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Background: Tumor-exosomes being reported to suppress or promote a cancer-directed immune response, we
used exosomes of the rat pancreatic adenocarcinoma BSp73ASML (ASML) to evaluate, whether and which steps in
immune response induction can be affected by tumor-exosomes and how the impaired responsiveness can be
circumvented.
Results: ASML-exosomes bind to and are taken up by all leukocyte subpopulations in vivo and in vitro, uptake by
CD11b+ leukocytes exceeding that by T and B cells. ASML-exosomes affect leukocyte proliferation via reduced
CD44v6 up-regulation and lck, ZAP70 and ERK1,2 phosphorylation, which can be compensated by dendritic cells
(DC). ASML-exosomes do not support Treg. Yet, impaired activation of anti-apoptotic signals is accompanied by
slightly increased apoptosis susceptibility. IgM secretion is unaffected; NK and CTL activity are strengthened,
ASML-exosomes co-operating with DC in CTL activation. ASML-exosomes transiently interfere with leukocyte
migration by occupying migration-promoting receptors CD44, CD49d, CD62L and CD54 during binding/
internalization.
Conclusion: ASML-exosomes might well serve as adjuvant in immunotherapy as they support leukocyte effector
functions and have only a minor impact on leukocyte activation, which can be overridden by DC. However,
exosome-induced modulation of immune cells relies, at least in part, on exosome uptake and message transfer. This
implies that depending on the individual tumor's exosome composition, exosomes may distinctly affect the
immune system. Nonetheless, whether immunotherapy can profit from using tumor-exosomes as adjuvant can
easily be settled beforehand in vitro.
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Exosomes, potent intercellular communicators that play
a pivotal role in physiological and pathological pro-
cesses [1] are found in all body fluids [2] and bind / are
taken up by selected targets [3]. Exosomes contain
function-competent proteins, mRNA and miRNA [1],
which can severely affect the target cells [4,5]. These
findings advocate for therapeutic use of exosomes,
which is particularly appreciated in immunotherapy, as
dendritic cell (DC)-exosomes, highly expressing MHCI,
MHCII, CD80 and CD86, are fully equipped to initiate
T cell activation [6,7].* Correspondence: margot.zoeller@uni-heidelberg.de
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reproduction in any medium, provided the orDC-exosomes being a promising means for immuno-
therapy [6,8], hope has been dampened by tumor-
exosomes interfering with immune response induction
[9] such that tumor growth becomes promoted [10].
Tumor-exosomes can inhibit lymphocyte, predominantly
CD4+ T cell proliferation in response to IL2, which is ac-
companied by impaired CD25 up-regulation and stron-
ger suppressive activity of regulatory T cells (Treg),
possibly due to exosome-associated TGFβ1 [11].
Impaired natural killer (NK) activity may rely on tumor-
exosomes inhibiting activation of Stat5, Jak3, cyclinD3
expression and perforin release [12] or on blocking NK
cells via NKG2D binding as far as exosomes express the
relevant receptors. Exosomal MICA*008 also provokes a
NKG2D-dependent reduction in NK cytotoxicity [13].
Tumor-exosomes affect T cells by inducing FAS-
mediated apoptosis [14] and by enzymatic activity, whichd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modulating tumor infiltrating leukocytes (TIL) [15].
Tumor-exosomes may also suppress an antigen-specific
response by inducing TGFβ1 and IL4 secretion and inhi-
biting DC maturation in draining lymph nodes [16].
Finally, tumor-exosomes can act as a decoy factor by
capturing tumor-directed drugs like therapeutic anti-
bodies as demonstrated for CD20 in hematological
malignancies [17].
On the other hand, tumor-exosomes can support im-
mune response induction. Exosomes express heat shock
proteins (HSP) [18]. Stress-inducible HSP70 functions
as an endogenous danger signal, promotes NK activa-
tion [19] and tumor cell lysis through granzyme B re-
lease. Exosomes recovered from heat-stressed tumor
cells also were superior in inducing a tumor-antigen-
specific cytotoxic T cell (CTL) response. Radiation-
induced exosomal release of HSP72 increased IL6,
TNFα, CTL and NK activity and induced costimulatory
molecule expression in DC [20,21]. In line with this,
vaccination with staphyloccocus enterotoxin A expres-
sing tumor-exosomes significantly inhibited tumor
growth and prolonged the survival time by increasing
IL2 and IFNγ secretion and by promoting T helper
(Th), CTL and NK activation [22]. Increased immuno-
genicity of exosomes from heat-stressed tumor cells is
further strengthened by exosomal chemokines that at-
tract and activate DC and T cells, whereby intratumor
injection efficiently inhibited tumor growth [23].
Tumor-exosomes can be a strong immunogen such that
tumor antigens, which are non-immunogenic when pre-
sented by tumor cells, induce a potent Th, CTL and B
cell response and lead to a decrease in Treg, when pre-
sented by tumor-exosomes [24].
We described that exosomes of the metastasizing
rat pancreatic adenocarcinoma ASML [25] support
premetastatic niche preparation in draining lymph
nodes [26]. Building on the proteome [26], mRNA
and miRNA profile of ASML-exosomes [http://www.
ncbi.nlm.nih.gov/geo, accession No GSE34739], we
elaborated changes in mRNA and protein expression
in a lymph node stroma line that readily takes up
ASML-exosomes. Besides others, ASML-exosomes
induced up-regulation of several chemokines and ad-
hesion molecules and down-regulation of molecules
controlling / inhibiting cell cycle progression (S.Rana
et al., submitted) that would rather favor than inhibit
cell migration and proliferation. Based on these find-
ings we asked, whether leukocytes, too, take-up
ASML-exosomes and how they respond. ASML-
exosomes do not inhibit immune response induction
by DC, they hamper Th activation under suboptimal
stimulatory conditions, but do not interfere with
effector functions.Results
DC-derived exosomes are valuable therapeutics in can-
cer due to their capacity to induce T cell activation [6].
In contrast, tumor-exosomes may be immunosuppres-
sive and counteract DC-exosomes [9]. To find modalities
that would allow interfering with undue tumor-exosome
activity, we explored tumor-exosome uptake and im-
mune response modulation in a rat model.Leukocyte binding and uptake of tumor-exosomes
Binding and uptake of dye-labeled ASML-exosomes by
leukocytes from central and peripheral lymphoid organs
was evaluated by flow-cytometry. Exosome binding
increased, when titrating exosomes from 10 μg/ml to
40 μg/ml and reached a plateau below 40 μg/ml (data
not shown). To be in the saturating dose, 40 μg/ml of
exosomes were used throughout. Exosomes readily
bound within 1 h. However, leukocyte stripping by acid
wash revealed that, with exception of peritoneal exudate
cells (PEC), few leukocytes had taken-up exosomes after
1 h co-incubation. Exosome uptake increased until 6 h
of co-incubation, when nearly all bound exosomes were
taken-up. Highest recovery was observed in PEC, fol-
lowed by spleen cells (SC), peripheral blood leukocytes
(PBL), bone marrow cells (BMC) and lymph node cells
(LNC). BMC behaved exceptionally, as a small popula-
tion showed a very high level of exosome uptake,
whereas thymocytes (TC) poorly took-up exosomes
(Figure 1A, Additional file 1). ASML-exosomes were
also taken-up by leukocytes in vivo. Dye-labeled exo-
some detection 24 h after i.v. injection confirmed prefer-
ential binding/uptake by PEC, followed by SC and PBL.
It was low in lymph nodes and the thymus, exosomes in
the thymus mostly being seen at the boundary between
cortex and medulla (Figure 1B,C). Detection of dye-
labeled exosomes after 48 h did not differ significantly
from that after 24 h and started to decrease after 72 h
(data not shown).
We next explored in vitro and in vivo, which subpopu-
lations in peripheral lymphoid organs preferentially take-
up ASML-exosomes. In vitro uptake was evaluated after
4 h co-incubation. With the exception of macrophages
(Mφ) (CD11b+) and DC (CD11c+), which most effi-
ciently took-up tumor-exosomes, uptake by CD4+, CD8+
and sIgM+ lymphocytes was in a comparable range and
uptake by granulocytes was lower (Figure 2A). A similar
profile of exosome uptake was seen 24 h after in vivo ap-
plication. Counterstaining of spleen and lymph node
sections revealed that exosomes co-localized only with
CD11b and CD11c, though exosomes were also seen in
CD4+ and CD8+ cells (Figure 2B,C). This suggested that
CD11b and CD11c, but not CD4 or CD8 are involved in
exosome uptake.
Figure 1 Tumor-exosome uptake by leukocytes. (A) BMC, TC, SC, LNC, PBL and PEC were incubated at 37°C with RhDHPE-labeled
ASML-exosomes for the indicated periods. Exosome binding and uptake (fluorescence after 2 acid washes) was evaluated by flow-cytometry:
Mean percent ± SD (3 experiments) of exosome+ leukocytes. Significant differences between exosome binding/uptake versus uptake:
*. (B,C) SP-Dio18(3)-labeled exosomes (200 μg) were injected i.v. and hematopoietic organs were excised after 24 h: (C) Mean percent ± SD (3 rats)
of exosome+ leukocytes evaluated by flow-cytometry. (D) Confocal microscopy showing representative examples of exosome+ cells in shock
frozen lymph node, spleen and thymus (arrow: boundary cortex/medulla) sections (scale bar left: 20 μm, right: 10 μm). Tumor-exosomes bind and
are taken up in vitro and in vivo by cells from all hematopoietic organs. Uptake is most rapid and abundant in PEC.
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integrin complexes to bind to integrin receptors
on stroma and endothelial cells [27,28], we asked
whether ASML-exosomes also bind to leukocyte adhe-
sion molecules. Besides CD11b+ and CD11c+ leuko-
cytes, exosomes were preferentially incorporated into
CD11a+, CD44+, CD49d+ and CD54+ leukocytes.
CD62L+ SC also showed a relative increase in tumor-
exosome uptake (Figure 3A). To investigate whether
these adhesion molecules are directly engaged, leuko-
cytes were pre-incubated with antibody. To avoid up-
take, antibody blocking studies were performed at 4°C
(30 min). A blockade of CD11b, CD11c, CD44,
CD49d, CD54 and CD62L on LNC and SC interfered
with exosome binding (2 h, 4°C). Binding to PEC was
most strongly inhibited by anti-CD11b and anti-CD54.
At the level of the exosomes, a blockade of thetetraspanins CD9 and CD81 interfered with binding
(Figure 3B).
Taken together, (i) tumor-exosomes bind and are
taken-up in vitro and in vivo by T cells, NK, B cells, DC,
Mφ and granulocytes; (ii) leukocyte subpopulations differ
in tumor-exosome uptake, which for ASML-exosomes is
highest for PEC and lowest for granulocytes; (iii) differ-
ences in tumor-exosome uptake depend on the availabil-
ity of leukocyte ligands for exosomal receptors, where
CD11b, CD11c, CD44, CD49d, CD54 and CD62L are
engaged in ASML-exosome binding; (iv) as previously
shown [28], exosomes bind via tetraspanin complexes.
Tumor-exosomes can inhibit leukocyte proliferation and
weaken apoptosis resistance
Exosome binding can initiate signal transduction via ac-
tivation of target cell ligands. However, exosomes also
Figure 2 Tumor-exosome uptake by leukocyte subpopulations. (A) LNC, SC, PBL and PEC were incubated with RhDHPE-labeled
ASML-exosomes for 6 h and stained with leukocyte subset-specific antibodies. The mean percent ± SD of marker+exosome+ / marker+ cells
(3 experiments) is shown. (B,C) In vivo uptake of SP-Dio18(3) labeled ASML-exosomes 24 h after i.v. application: (B) flow-cytometry of dispersed
cells. The mean percent ± SD of marker+exosome+ / marker+ cells (3 rats) is shown. (C) Confocal microscopy of shock frozen tissue sections
(spleen sections were stained with anti-sIgM, lymph node sections with anti-CD4, -CD8, -CD11b and -CD11c. For lymph node sections stained
with anti-CD4 and anti-CD11b a higher magnification is included (scale bar spleen: 20 μm, lymph nodes: 10 μm). (A,B) Significant differences in
the % exosome+marker+ cells as compared to exosome+ cells in the total organ: *. Exosomes are taken up by cells of all major leukocyte
subpopulations.
Zech et al. Cell Communication and Signaling 2012, 10:37 Page 4 of 17
http://www.biosignaling.com/content/10/1/37are taken-up by target cells and the uptaken exosomes
exert long-lasting effects on their targets [29]. Further-
more, as exosome binding and uptake proceed concomi-
tantly, it is difficult to define effects initiated exclusively
by binding. Finally, the impact of ASML-exosomes
on a lymph node stroma line was analyzed in detail
showing that proteins, mRNA and miRNA are trans-
ferred, target cells being mostly affected by exosomal
miRNA [26], http://www.ncbi.nlm.nih.gov/geo, accession
No GSE34739, Rana et al., submitted. For these reasons
we evaluated the impact of uptaken exosomes on
leukocyte activity, the exosomes being present through-
out the culture period, but at least for 6 h.
Though ASML-exosomes did not promote a major
redistribution of T cell subsets (Additional file 2), prolif-
erative activity, evaluated by 3H-thymidine incorporation,
was impaired. The response to IL2 and tumor-lysate (as
nominal antigen) was more strongly affected than theresponse to the polyclonal T cell stimulus ConA. Low
proliferative activity in the absence of a stimulus and in
response to LPS was not affected. CFSE dilution con-
firmed these findings. Notably, when LNC were sup-
ported by antigen-loaded DC, proliferation-suppressive
activity of ASML-exosomes was effaced (Figure 4A,B).
Further, tumor-exosomes did not affect DC maturation.
CD11c, CD80 and CD86 expression was unimpaired and
MHCII, IFNγ and CXCR4 expression was augmented,
when DC were matured in the presence of ASML-
exosomes (Figure 4C).
Reduced proliferative activity could have been due to
myeloid-derived suppressor cell (MDSC) or Treg expan-
sion, apoptosis induction or impaired T cell activation by
ASML-exosomes.
Independent of the presence of DC, tumor-exosomes
did not promote MDSC or Treg expansion (Figure 5A,B).
However, ASML-exosome-treated lymphocytes showed
Figure 3 Adhesion molecules engaged in tumor-exosome uptake. (A) Cells as in (Figure 2A) were stained with adhesion molecule-specific
antibodies: representative examples and mean percent ± SD of marker+exosome+ / marker+ cells (3 experiments). (B) LNC, SC and PEC or
exosomes were pre-incubated with the indicated antibodies (30 min, 4°C). After washing, cells were co-incubated with dye-labeled exosomes 2h,
4°C: representative examples and mean percent ± SD (3 experiments) of exosome+ cells. (A) Significant differences in the % exosome+marker+
cells as compared to exosome+ cells in the total organ: *, (B) significant differences compared to control IgG treatment: *. There is evidence for
an engagement of CD11b, CD11c, CD44, CD49d, CD54 and CD62L in exosome uptake.
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Furthermore, up-regulation of the accessory molecule
CD44v6 [30], though not of CD25 and CD28, was
reduced in IL2 or ASML-lysate stimulated cells. CD44v6
expression was not significantly reduced in the presence
of ConA or DC (Figure 5D).
Having excluded MDSC and Treg to account for
reduced proliferative activity in the presence of ASML-
exosomes, we searched for the mechanism underlying
the slightly increased apoptosis susceptibility. CD95L
(CD178) expression was slightly increased in LNC and
SC co-cultured with ASML-exosomes that was not seen
in the presence of DC. TNFα expression was only
increased in SC, TRAF4 expression was not affected and
Trail expression was reduced (Figure 6A). Despite slight
CD95L up-regulation, Caspase8 expression, Caspase9
cleavage and Caspase3 activation were unaltered
(Figure 6B), which excludes CD95L up-regulation to
contribute to lymphocyte suicide. Searching for changes
in the mitochondrial pathway of apoptosis and apoptosis
protection revealed unaffected Bax, Bid, Bak, Smac/
Diablo, XIAP and cytochromeC expression in ASML-exosome-treated LNC and SC (Figure 7A). Instead, PI3K
and Akt phosphorylation was slightly, but significantly
reduced. BAD phosphorylation and Bcl2 and BclXl ex-
pression also was slightly affected in LNC and SC and,
though mitigated, in cultures containing DC (Figure 7B,
Additional file 3A). Thus, impaired anti-apoptotic signal-
ing may account for the slightly increased lymphocyte
apoptosis-susceptibility.
Reduced CD44v6 expression in LNC and SC was ac-
companied by a reduction in Lck, ZAP70 and Lat phos-
phorylation and impaired activation of the MAPK
(ERK1,2) cascade. The JNK pathway (JNK, c-jun) and
NFκB (IκB phosphorylation) were not affected. When
activation of exosome-treated lymphocytes was sup-
ported by ASML-lysate-pulsed DC, Lck and ERK1,2
phosphorylation was still reduced, but ZAP70 and LAT
phosphorylation was unimpaired (Figure 8, Additional
file 3B).
Taken together, tumor-exosomes affected lymphocyte
proliferation, most pronounced in response to IL2.
Reduced proliferation was not due to MDSC or Treg ex-
pansion. Instead, reduced CD44v6 expression could
Figure 4 ASML-exosomes and leukocyte proliferation. Lymphocytes were stimulated for 72 h as indicated with/without ASML-exosomes.
Where indicated, cultures additionally contained ASML lysate-pulsed DC (LNC:DC = 10:1). (A) Mean ± SD (triplicates) of 3H-thymidine incorporation.
(B) Examples of CFSE dilution in LNC and SC cultured for 72 h and mean percentage (triplicates) of cells that did progress through 0–4 cycles.
Significant differences to cultures not containing ASML-exosomes are shown. (C) BMC-derived DC were cultured as described in MM. During the
last 24 h of culture in the presence of LPS, ASML-exosomes were added where indicated: Mean percent ± SD (3 experiments) of CD11b+, CD11c+,
CD80+, CD86+, MHCII+, IFNγ+ and CXCR4+ cells (flow-cytometry). (A,C) Significant differences in the presence of ASML-exosomes: *. Exosomes
inhibit lymphocyte proliferation, which can be circumvented by activated DC.
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[31,32] and, as CD44 associates with Lck [33], for miti-
gated T cell activation, which had consequences mainly
on MAPK pathway activation. However, CD28 expres-
sion and DC activation not being affected, reduced
CD44v6 expression was mostly compensated in the pres-
ence of DC.
Tumor-exosomes support effector lymphocytes
ASML-exosomes did not affect B cell proliferation in re-
sponse to LPS (Figure 4A) and IgM secretion was not
reduced in IL2, LPS and ASML-lysate stimulated SC,
LNC, PEC or in DC-supported SC co-cultured with
ASML-exosomes (Figure 9A). Neither sIgM nor CD81
expression was affected (Additional file 4). Nonetheless,fyn, syk and PLCγ phosphorylation was slightly reduced
in SC, but not in PEC co-cultured with ASML-
exosomes. There was no evidence for concomitant SHP
up-regulation (Figure 9B).
Tumor-exosomes promoted NK and CTL activity. NK
activity, evaluated against highly NK-susceptible AS cells
[34] was most strongly supported by ASML-exosomes in
response to IL2. When co-cultured with NK-enriched
NKR-P1B+ SC, even 10 μg/ml ASML-exosomes sufficed
for an increase in cytotoxic activity. Furthermore, gran-
zymeB, IL2, IFNγ, TNFα, CD25 and weakly CD95L ex-
pression was upregulated in IL-2 stimulated NKR-P1B +
SC, when cultured in the presence of ASML exosomes.
Stat5 phosphorylation and cyclinD3 expression was also
slightly increased (Figure 9C-E). ASML-exosomes also
Figure 5 ASML-exosomes, immunosuppression, apoptosis and activation markers. Leukocytes were stimulated as described in Figure 4. (A)
Mean percent (3 experiments) of Gr1+, CD11b+ and Gr1+CD11b+ (MDSC) cells. (B) examples of CD4+CD25+, CD4+FoxP3+ and CD25+FoxP3+ cells
and mean percent ± SD (3 experiments) of CD4+CD25+FoxP3+ cells. (C) Representative examples of AnnexinV/PI staining and mean percent ± SD
(3 experiments) of AnnV-FITC+/AnnV-FITC+/PI+ cells. (D) Mean percent ± SD (3 experiments) of CD25+, CD28+ and CD44v6+ cells. (C,D) Significant
differences in the presence of ASML-exosomes: *. There is no evidence for ASML-exosomes affecting MDSC or Treg. However, apoptosis
susceptibility is slightly increased and expansion of CD44v6+ cells is impaired.
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cells, and exerted co-operative activity with tumor-
lysate-loaded DC, which by themselves stimulated CTL
activation. ASML-exosomes also promoted, albeit
weakly, activation of auto-reactive CTL (syngeneic
blasts) (Figure 9F).
Though primary B cell responses were unimpaired, the
discrete differences in activation of signaling molecules
associated with B cell activation suggest ASML-
exosomes to possibly affect B cell response regulation.
ASML-exosomes strongly promoted NK and CTL activ-
ity, the latter in co-operation with DC.
Tumor-exosomes and T cell migration
A tumor-specific immune response can only become ef-
fective, when activated lymphocytes reach the tumor
[35]. Thus, an impact of ASML-exosomes on T cell mi-
gration could be a hindrance.
When evaluating magnetic bead-enriched lymph node
T cell migration in the presence of ASML-exosomes,
PMA-stimulated T cell migration was hardly affected,but that of IL2 and ASML-lysate stimulated T cells was
mitigated (Figure 10A). As adhesion molecule expression
was not or minimally (CD18 and CD62L) affected
(Additional file 5), we questioned whether ASML-
exosomes may transiently occupy adhesion molecules
required for migration. Indeed, migration of lymphocytes
that had been pretreated, but did not contain ASML-
exosomes during migration was far less reduced
(Figure 10A). This finding pointing towards impaired
availability of adhesion molecules contributing to the
ASML-exosome-mediated blockade in T cell migration,
we controlled, which antibodies interfere with migration
in the absence of exosomes. T cell migration was
strongly affected by anti-CD49d, anti-CD44, anti-CD62L
and anti-CD54 (Figure 10B). As CD44, CD49d, CD62L
and CD54 are engaged in exosome binding (Figure 3B),
we speculated that exosomes should not be inhibitory
for T cells pre-incubated with these antibodies. In fact,
ASML-exosomes did not further reduce migration of
antibody-pre-incubated T cells (Figure 10C). From there
we conclude that the inhibitory effect of ASML-
Figure 6 ASML-exosomes and death receptors. Leukocytes were stimulated as described in Figure 4. Expression of (A) death receptors and (B)
caspases was evaluated by flow-cytometry. Representative examples and mean percent ± SD (3 experiments) of stained cells; significant
differences in the presence of ASML-exosomes: *. ASML-exosomes do not promote caspase activation.
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sion molecules required for migration. In line with this,
SDF1 and CXCR4 expression was not reduced, FAK and
ezrin phosphorylation was not and src phosphorylation
was only slightly impaired in ASML-exosome treated T
cells (Figure 10D).
Thus, exosome binding and/or the internalization of
the exosome ligand(s) during uptake mostly accounts for
transiently impaired T cell migration.
Tumor-exosomes and leukocyte activation in vivo
To control for the impact of tumor-exosomes on
leukocyte activation in vivo, BDX rats received subcuta-
neous injections of 2×106 ASML lysate-loaded DC and
2-times/week 500 μg ASML-exosomes (i.v.). Rats were
bled and sacrificed 3d after the 3rd DC injection, the
draining axillary and inguinal lymph nodes and the
spleen were excised and analyzed.
DC vaccination was accompanied by an >2-fold in-
crease in the number of draining LNC, which was
further increased, when rats received concomitantly
ASML-exosomes (Figure 11A). DC vaccinationpromoted a slight expansion of CD4+, CD8+ and CD11c+
cells. Exosomes induced expansion of CD11b+ cells. DC
vaccination also induced CD25, CD28, CD44v6, CD80,
CD86, IL2, IL12 and IFNγ upregulation. Only CD25 and
CD80 upregulation was not seen in rats concomitantly
receiving ASML-exosomes. (Figure 11B, Additional file
6A). Exosome application did not affect Treg and an
expansion of MDSC was only seen in the peripheral
blood, though not in rats concomitantly receiving DC
(Figure 11C, Additional file 6B). Unexpectedly, ASML-
exosomes did not inhibit, but rather promoted LNC,
SC and, most pronounced, PBL proliferation in vivo.
High proliferative activity of lymphocytes from rats re-
ceiving DC was not affected by concomitant ASML-
exosome application. This was independent of whether
lymphocytes were restimulated in vitro by IL2, ASML
lysate or ASML lysate plus exosomes (Figure 11D).
The cytotoxic activity of LNC and SC also was unim-
paired in rats receiving lysate-pulsed DC plus ASML-
exosomes and lymphocytes from rats treated with
ASML-exosomes showed increased CTL activity com-
pared to untreated controls. NK activity was hardly
Figure 7 ASML-exosomes and activation of pro- and anti-apoptotic molecules. Leukocytes were stimulated as described in Figure 4.
Expression of (A) pro-apoptotic molecules and (B) anti-apoptotic molecules was evaluated by flow-cytometry. Mean percent ± SD (3 experiments)
of stained cells; significant differences in the presence of ASML-exosomes: *. ASML-exosomes slightly affect activation of the PI3K/Akt pathway.
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ment (Figure 11E).
With the exception of an increase in MDSC in the
peripheral blood of ASML-exosome-treated rats, these
ex vivo data confirm the results obtained after
in vitro co-culture and show that in vivo ASML-
exosomes support immune response induction by
tumor-lysate-loaded DC.
Discussion
Tumor-exosomes are discussed to possibly provide a
hindrance in immunotherapy by suppressing immune
response induction as well as immune effector cells [9].
However, opposing findings have also been observed
[23,36]. We approached the question using exosomes of
a highly metastatic rat pancreatic adenocarcinoma,
where pancreatic adenocarcinoma are known for their
intense interaction with the surrounding tissue including
TIL [37]. Though ASML-exosomes interfere with
leukocyte activation in vitro, they did not affect or sup-
ported effector cells and a reduction in T cell migrationwas transient. These findings - not excluding immuno-
suppression by other tumor-derived vesicles – argue
against tumor-exosomes being a hindrance in
immunotherapy.
Tumor exosome binding and uptake
Tumor-exosomes bind and are taken-up by leukocytes
in central and peripheral lymphoid organs, though bind-
ing/uptake varies considerably being highest for PEC
and lowest for TC. As a very similar profile of binding/
uptake was observed in vitro and in vivo, the low uptake
by TC cannot exclusively rely on poor accessibility of
the thymus. Also, the high recovery of exosomes in PEC
cannot be explained by "first station" capture that would
be the spleen after i.v. injection. Thus, exosome uptake
is a directed process that is particularly efficient in Mφ
and DC.
Exosome uptake by solid organ-derived cells mostly
proceeds via binding of tetraspanin-associated adhe-
sion molecules to their target cell ligands [27,28].
Antibody-blocking studies revealed CD11 integrins,
Figure 8 ASML-exosomes and TCR activation. Leukocytes were stimulated as described in Figure 4. Expression of molecules involved in TCR
signaling was evaluated by flow-cytometry. Representative examples and mean percent ± SD (3 experiments) of stained cells; significant
differences in the presence of ASML-exosomes: *. In the presence of ASML-exosomes activation of lck and TCR downstream kinases of the MAPK
pathway is impaired. Both effects are strongly mitigated in the presence of DC.
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exosome uptake, where up-regulated CD44 and
CD49d expression on activated lymphocytes [38] and
CD11c on activated DC [39] could facilitate exo-
some binding. Similar to AS-exosomes (28), ASML-
exosomes mostly use (CD9 and CD81) tetraspanin
complexes for leukocyte binding. Uptake by Mφ may
proceed distinctly from that by lymphocytes. Binding
of Annexins to scavenger receptors can play a role in
exosome uptake [40,41]. The more rapid exosome up-
take by Mφ that is mostly inhibited by anti-CD11b
argues for Annexin possibly being important in exo-
some uptake by Mφ.
Taken together, tumor-exosomes uptake by CD11b+
Mφ may preferentially proceed via scavenger receptors,
uptake by lymphocytes and dendritic cells via adhesion
molecule ligands for exosomal receptors in tetraspanin
complexes. Exosome uptake by leukocytes will vary
according to the leukocyte ligands as well as exosomal
(tetraspanin)-adhesion molecule complexes.Tumor-exosomes and lymphocyte activation
Proliferation of T cells stimulated in the presence of
tumor-exosomes was reduced, most pronounced when
stimulated by IL2.
Tumor-exosomes can strengthen MDSC [42,43] and
Treg expansion/activation [11,44,45], but also impair Treg
expansion [24]. We did not observe any effect on Treg
and only in vivo an increase in MDSC in the peripheral
blood. These findings exclude ASML-exosomes to im-
pair lymphocyte activation due to active suppression.
Tumor-exosomes can induce lymphocyte apoptosis via
CD95L and TRAIL [46,47]. Although there was a slight
increase in CD95L+ lymphocytes and in early (AnnV
+/PI-) apoptotic lymphocytes, co-culture with ASML-
exosomes did not suffice to initiate receptor-mediated
apoptosis or to activate the mitochondrial apoptosis
pathway. Instead, ASML-exosomes slightly affected acti-
vation of anti-apoptotic molecules of the PI3K/Akt path-
way. This could well be a consequence of impaired
CD44v6 upregulation, CD44v6 supporting liberation of
Figure 9 ASML-exosomes and effector lymphocytes. (A,B) SC, LNC and PEC were stimulated with IL2, LPS or ASML lysate with/without
ASML-exosomes: (A) Supernatants were harvested after 4d to evaluate IgM secretion by ELISA. (B) Expression of B cell activation-related signal
transduction molecules was evaluated by flow-cytometry after 2d (mean values ± SD, 3 experiments). (C) SC and NKR-P1B+ cells were cultured in
the presence of 100U IL2/ml or ASML-lysate for 2d. NK cytotoxicity was evaluated with 3H-thymidine labeled AS target cells. (D) NKR-P1B+ cells
were cultured in the presence of 100U IL2/ml and titrated amounts of ASML-exosomes. Cytotoxicity was evaluated as in (C) after 2d of co-culture.
(E) NKR-P1B+ cells were cultured in the presence of 100U IL2/ml and 40 μg/ml ASML-exosomes for 2d. Expression of granzymeB, IL2, IFNγ, TNFα,
CD25, CD95L, p-Stat5 and CyclinD3 was evaluated by flow cytometry. (F) LNC were cultured in the presence of ASML-lysate for 8d. Where
indicated, cultures contained ASML lysate-loaded DC. CTL activity was evaluated with 3H-thymidine labeled ASML and BDX blast target cells:
(C,D,F) Mean percent ± SD (triplicates) of cytotoxicity at the indicated E:T ratios. (A-F) Significant differences in cultures containing
ASML-exosomes: *. Tumor-exosomes do not hamper a primary B cells response to T cell-dependent or T cell-independent stimuli. But, activation
of fyn, syk and PLCγ are slightly impaired. Tumor-exosomes strengthen NK and CTL activity.
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pathway (31,32).
Proliferation being most strongly suppressed in re-
sponse to IL2, but not in the presence of DC, also points
towards an impact of ASML-exosomes on accessory
molecule, particularly CD44 activation. During lympho-
cyte activation CD44 associates with lck, which becomes
phosphorylated and contributes to ZAP70 phosphoryl-
ation [48]. CD44v6 also can directly promote MAPK
pathway activation [26,49]. In cultures containing
ASML-exosomes, lck, ZAP70, LAT and ERK1,2 phos-
phorylation was significantly, though not strongly
reduced, possibly due to support by other accessory
molecules like CD25, CD28 or CD40L. Notably, in co-
cultures with DC, lck and ERK1,2 phosphorylation, but
not ZAP70 and LAT phosphorylation remained reduced.
Thus, in the presence of antigen-loaded DC showinghigh CD40 expression, impaired CD44v6-initiated sig-
naling becomes invalidated.
Taken together, tumor-exosomes inhibit Th expan-
sion/activation in response to IL2. The inhibitory effect
can be circumvented by provision of appropriate second
signals, e.g. via DC. There was no evidence for exo-
somes affecting signals directly initiated by TCR engage-
ment. In line with this, no changes in signal
transduction molecule activation were seen after 1 h co-
incubation of leukocytes with exosomes (data not
shown). Moreover, ASML-exosomes hardly promote
apoptosis and not immunosuppression, which findings
were confirmed in vivo.
Tumor-exosomes and lymphocyte effector functions
ASML-exosomes did not interfere with a primary B
cell response. Nonetheless, fyn, syk and PLCγ
Figure 10 ASML-exosomes and T cell migration. T cells were stimulated as indicated for 24 h. (A-C) Stimulated T cells were seeded in
RPMI/1%FCS in the upper part of a Boyden chamber, the lower part contained RPMI/20%FCS. Where indicated, T cells stimulated in the presence
of ASML-exosomes were washed, evaluating migration in the absence of ASML-exosomes. The percentage of migrating cells was evaluated after
4 h at 37°C. (B) T cells were stimulated for 24 h with PMA. Before migration, cells were incubated with the indicated antibodies (30 min, 4°C).
(C) T cells were stimulated, washed and incubated with the indicated antibodies (30 min, 4°C). Migration was evaluated in the presence/absence
of ASML-exosomes. (A-C) Mean percent ± SD (triplicates, 3 experiments) of migrating cells. (A) Significant differences in cultures containing or
pre-incubated with ASML-exosomes: *, (B,C) significant antibody inhibition: *, (C) significant inhibition in the presence of ASML-exosomes: s.
(D) Migration-related signaling molecule including SDF1 and CXCR4 expression was evaluated by flow-cytometry. Mean percent ± SD (3
experiments) of stained cells, significant differences in cultures containing ASML-exosomes: *. Tumor-exosomes affect T cell migration. This is due
to a blockade of migration-relevant adhesion molecules engaged in exosome uptake. Up-taken exosomes hardly affect T cell migration.
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exosomes did not induce activation of phosphatases,
which can dephosphorylate syk and thereby account
for PLCγ down-regulation [50], we cannot exclude that
ASML-exosomes may have some bearing on B cell re-
sponse regulation.
ASML-exosomes strongly stimulated NK activity in
the presence of IL2. Tumor-exosomes can suppress NK
activity by inhibition of JAK/STAT pathway signal trans-
duction, reduced perforin release or a blockade of NKactivating receptors [12,13], but also can stimulate NK
cells by high HSP expression [19,21], as known for
ASML-exosomes [26]. Irrespective of the constitutively
high NK activity of BDX rats [51], pronounced induction
of GranzymeB and IFNγ expression in NKR-P1B cells in
the presence of ASML-exosomes argues for exosomes-
supported NK activation rather than suppression. The
same accounts for CTL, where ASML-exosomes effi-
ciently stimulated tumor-specific and only to a minor
degree, autoreactive CTL. Importantly, ASML-exosomes
Figure 11 In vivo impact of ASML-exosomes on leukocyte activation. Rats received 3-times 2x106 DC, subcutaneously and/or 7-times 500 μg
ASML-exosomes, i.v. as described in MM. Rats were sacrificed 3d after the 3rd DC application to analyze the draining LNC, SC and PBL.
(A) Number of draining LNC (mean ± SD, 3 rats), (B) leukocyte activation markers, IL2, IL12 and IFNγ expression (flow cytometry, mean ± SD, 3
rats and representative examples), (C) MDSC (flow cytometry, mean ± SD, 3 rats), (D) 3H-thymidine incorporation after 3d in vitro culture and
(E) cytotoxic activity against ASML and AS (NK susceptible) targets after 10d in vitro culture in the presence of ASML lysate (mean ± SD,
triplicates). (A-E) Significant differences to lymphocytes from untreated rats: *, differences between lymphocytes from rats receiving DC or DC
plus ASML-exosomes are indicated as ns (not significant) or s (significant, p <0.01). In vivo, ASML-exosomes support recruitment and/or
proliferation of draining LNC and CD11b, CD86, IL12 and IFNγ expression. Despite an increase in MDSC in the peripheral blood, ASML-exosomes
support DC vaccination-induced T cell expansion and cytotoxic activity.
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due to tumor-exosome uptake by DC [36].
It should be mentioned that according to our protocol
of prolonged leukocyte – exosome co-incubation, we
missed binding-initiated activation of signaling cascades
and changes in signaling pathway activation could likely
be due to transferred exosomal proteins, mRNA or
miRNA [5,7], where exosomal miRNA might be domin-
ating (Rana et al., submitted). However, irrespective of
whether exosomes binding or uptake slightly mitigated
activation of several signal transduction pathways,
ASML-exosomes did not hamper or stimulated lympho-
cyte effector functions in vitro and lymphocyte activa-
tion was not impaired in vivo. Thus, increased NK and
CTL activity argues for ASML-exosomes as an immuno-
therapy supporting regimen.Tumor-exosomes and leukocyte migration
As activated leukocytes need to reach the tumor, the im-
pact of ASML-exosomes on T cell migration became im-
portant. Migration was significantly impaired only when
leukocytes were exposed to exosome during migration
and antibody blocking studies confirmed that exosomes
only transiently interfered with lymphocyte migration by
occupying or co-internalizing with their migration-
relevant ligands, CD44, CD49d, CD62L and CD54
[38,52]. Instead, uptaken exosomes did not affect
leukocyte migration. These findings are in line with
ASML-exosomes not affecting src, FAK and ezrin phos-
phorylation and SDF1 and CXCR4 expression. Upregu-
lated CXCR4 expression in draining LNC after i.v.
application of ASML-exosomes and leukocyte recruit-
ment into the draining node after subcutaneous ASML-
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hampering leukocyte migration in vivo.
Conclusion
ASML-exosomes were taken up by leukocytes and inter-
fered, though not severely, with T cell expansion in vitro,
which could be circumvented by supportive regimens
like DC. They did not promote Treg expansion and only
in vivo a slight increase in MDSC was seen. T cell migra-
tion was only transiently impaired during exosome up-
take. Importantly, ASML-exosomes supported effector
cells and cooperated with DC [23], whereby tumor-
exosomes can become a stronger immunogen than a
membrane-bound or soluble tumor antigen [24,36]. In
addition, tumor-exosomes can provide a reliable source
of tumor antigens in tumors where immunogenic en-
tities are unknown. Nonetheless, as exosome-mediated
intercellular communication may be dominated by
transferred miRNA [5], exosomes of different tumors
could distinctly affect the immune system, which can be




The rat pancreatic adenocarcinoma lines ASML and
BSp73AS (AS) [25] were maintained in RPMI1640/10%
FCS. Confluent cultures were detached with trypsine or
EDTA and split. ASML cells are NK resistant, AS cells
are highly NK susceptible [34].
Antibodies are listed in Additional file 7.
Exosomes were separated by ultracentrifugation and
sucrose density gradient [28]. In brief, cells were cul-
tured (48 h) in serum-free medium. Cleared superna-
tants (2×10min, 500 g, 1×20min, 2000 g, 1x30min,
10000 g) were centrifuged (90 min, 100000 g) and
washed (PBS, 90 min, 100000 g). Crude exosome pre-
parations were suspended in 2.5 M sucrose, overlaid by
a continuous sucrose gradient (0.25 M-2 M) and centri-
fuged (15 h, 150000 g). To exclude an impact of sucrose
gradient centrifugation on exosome activity, sucrose
gradient-purified exosomes were compared with the
100000 g pellet that was filtered through 0.20 μm mem-
branes to remove, at least, larger non-exosome vesicles.
Comparative analyses of sucrose-gradient enriched and
1000000 g/0.2 μm filtered exosomes are shown in Add-
itional file 8. As we did not observe impaired activity of
sucrose-gradient enriched exosomes, all other experi-
ments were performed with the latter exosome popula-
tion. Where indicated, exosomes were prepared after
rhodamine-DHPE or SP-Dio18(3) (Invitrogen, Karlsruhe,
Germany) labeling (60 min, 4°C). Relative fluorescence
intensity was evaluated at 540 nm excitation, 590 nm
emission or 497 nm excitation, 513 nm emission,respectively, and adjusted to rhodamine-DHPE or SP-
Dio18(3) standards. ASML-exosomes have been charac-
terized for protein composition [26], mRNA and miRNA
content [http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE34739].
Cell and rat tissue preparation
Heparinized peripheral blood was collected by heart
puncture. PBL were collected after Ficoll-Hypaque gradi-
ent centrifugation. PEC were collected flushing the peri-
toneal cavity with 10 ml PBS/heparin. BMC were
collected from femora and tibiae, flushing the bones
with 5 ml PBS. SC and LNC were obtained by pressing
the organs through fine gauze. Where indicated, cells
were CFSE (Invitrogen, Karlsruhe, Germany) labeled.
Subpopulations were enriched by magnetic-bead sorting
(Miltenyi, Mönchen-Gladbach, Germany). DC were gen-
erated in vitro from BMC. BMC (2×106) were cultured
in 10 cm diameter Petri dishes in 10 ml RPMI1640, sup-
plemented with 10 ng/ml rrGM-CSF and 2 ng/ml rrIL-4.
On day 3 of culture, additional 10 ml medium was
added, exchanging half of the medium on day 6. Loosely
adherent cells, harvested after 8d, were seeded in new
Petri dishes in 10 ml medium containing 1 μg/ml LPS
for 24 h to induce DC maturation. Matured DC were
harvested on day 9, washed and loaded in serum-free
RPMI with ASML-lysate (lysate of 3 cells/1 DC, over-
night, 37°C).
Exosome binding and uptake
Exosome binding/uptake in vitro was evaluated after
1 h-12 h co-incubation of dye-labeled exosomes with
leukocytes. To differentiate between binding and uptake,
bound exosomes were removed by two acid washes
(PBS/HCl, pH 2.5) (stripping) evaluating exosome
uptake by flow cytometry after fixation and per-
meabilization. When evaluating exosome binding struc-
tures on leukocytes or exosome targeting structures, leu-
kocytes were incubated with the indicated antibodies for
30 min at 4°C and washed 2× with an excess of PBS.
Dye-labeled exosomes, incubated with antibodies for
30 min at 4°C, were resuspended in 50 ml of PBS and
centrifuged for 90 min at 100000 g. Antibody-coated
washed cells / exosomes were co-incubated for 2 h at 4°
C, washed 2-times with an excess of PBS and immedi-
ately analyzed by flow cytometry. The short incubation
time at 4°C, though resulting in a lower binding rate, is
mandatory to avoid exosome uptake.
Flow cytometry followed routine procedures. Where
indicated, cells were fixed and permeabilized. Apoptosis
was determined by AnnV/PI staining. Cell cycling was
determined by CFSE dilution in labeled leukocytes. Sam-
ples were analyzed by a FACSCalibur and the Cell Quest
Program.
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Sections (7 μm) of shock frozen tissues from rats that
had received an i.v. injection of 200 μg dye-labeled
exosomes were counterstained with HE or marker-
specific antibodies according to routine procedures.
Digitized images were generated using a Carl Zeiss
LSM780 confocal microscope and software Carl Zeiss
Axioview Rel. 4.6.
Proliferation assay
LNC and SC were titrated (2×105-2.5×104 cells/well) in
96 well plates with/without 104 ASML lysate-loaded
DC and/or 40 μg/ml exosomes. Cells were cultured for
3d adding 10 μCi/ml 3H-thymidine during the last
16 h. 3H-thymidine incorporation was evaluated in a
β-counter.
Cytotoxicity assays
CTL activity was evaluated after stimulating LNC with
ASML lysate for 7d in RPMI/10%FCS/10U IL2/ml.
ASML cells and, as control, syngeneic lymphoblasts
(ConA-stimulated LNC) were used as targets. NK activ-
ity was evaluated after 2d of culture of SC or NKR-P1B+
cells [53] (magnetic bead separation) in the presence of
100U IL2/ml using AS cells as target. Cytotoxicity was
evaluated using the JAM assay [54]. In brief, 3H-thymi-
dine-labeled target cells (1×104/well) were seeded on
titrated numbers (1x106-2.5×105) of effector cells in 96
well plates. After 6 h at 37°C, plates were harvested, and
radioactivity was determined in a β-counter. Cytotoxicity
is presented as % cytotoxicity = 100 × (counts in control
well - counts in test well) / (total counts/well).
ELISA
IgM secretion as evaluated according to standard ELISA
protocols. Plates were coated with 10 μg/ml anti-rIgM
(overnight, 4°C). After washing and blocking, superna-
tants of cultures as described above were seeded on the
plates overnight. Plates were washed (PBS/0,01%
Tween20) and biotinylated anti-rIgM (2 μg/ml in PBS/
0.5%BSA) was added. After incubation (2 h, 37°C), wash-
ing (6x, PBS/0.01%Tween20) and streptavidin-alkaline
phosphatase enzyme-conjugate incubation (45 min,
room temperature), BCIP/NBT substrate was added. OD
(triplicates) was measured at 495 nm.
Migration assay
Cells were seeded in the upper part of a Boyden chamber
in 50 μl RPMI/0.1%BSA with/without 40 μg/ml exo-
somes. The lower part, separated by a 5 μm pore size
polycarbonate-membrane (Neuroprobe, Gaithersburg,
MD, USA) contained 30 μl RPMI/20%FCS. Leukocytes in
the lower chamber were counted after 4 h. Whereindicated, cells were pre-incubated with antibody (10 μg/
ml). Migration is presented as % of input cells.
In vivo experiments
BDX rats received an i.v. injection of SP-Dio18(3)-labeled
exosomes (200 μg/rat). After 24 h, rats were bled, sacri-
ficed and lymphatic organs were excised. For vaccin-
ation, rats received 3 subcutaneous injections of 2×106
ASML-lysate-loaded DC in 10d intervals. Starting with
the first DC application, rats received 500 μg ASML-
exosomes, 2-times/week. Rats were sacrificed 3d after
the 3rd DC application. Animal experiments were
Government-approved (Baden-Württemberg, Germany).
Statistical analysis
Assays were repeated at least 3 times. P-values <0.05
(two-tailed Student’s t-test) were considered significant.
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